1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study

BACKGROUND: In the STORM CHASER phase 3 post-exposure prophylaxis study, 300-mg intramuscular (IM) AZD7442 (tixagevimab/cilgavimab) reduced symptomatic COVID-19 by 33.3% vs placebo at primary analysis (P=0.212; median follow-up: 183 days) and was well tolerated. We report final safety data from STOR...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Myron J, Ustianowski, Andrew, Thissen, Jesse, Seegobin, Seth, Beavon, Rohini, Dey, Kanika, Kelly, Elizabeth J, Near, Karen A, Streicher, Katie, Kiazand, Alexandre, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677026/
http://dx.doi.org/10.1093/ofid/ofad500.1190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677026/
http://dx.doi.org/10.1093/ofid/ofad500.1190

Ejemplares similares